In this section
@article{Alagaratnam:2025:10.1097/qad.0000000000004040,
author = {Alagaratnam, J and Kelly, N and Dustan, S and Naous, N and Nwanbila, M and Byrne, R and Girometti, N and Asboe, D and Taylor, GP and Boffito, M},
doi = {10.1097/qad.0000000000004040},
journal = {AIDS},
pages = {95--98},
title = {Proviral HIV DNA sequencing to inform suitability for long-acting injectable cabotegravir/rilpivirine},
url = {http://dx.doi.org/10.1097/qad.0000000000004040},
volume = {39},
year = {2025}
}
TY - JOUR
AB - Increasingly, people attending HIV services are requesting long-acting injectable (LAI) antiretroviral treatment (ART). However, without HIV RNA resistance-associated mutation results, individuals are considered unsuitable for LAI ART. We present our experience of sequencing proviral HIV DNA in 30 individuals to inform suitability for LAI ART, of whom 23 were considered suitable. In conclusion, optimization of diagnostic tools such as proviral HIV DNA sequencing to confirm suitability for LAI ART would be a welcome addition.
AU - Alagaratnam,J
AU - Kelly,N
AU - Dustan,S
AU - Naous,N
AU - Nwanbila,M
AU - Byrne,R
AU - Girometti,N
AU - Asboe,D
AU - Taylor,GP
AU - Boffito,M
DO - 10.1097/qad.0000000000004040
EP - 98
PY - 2025///
SN - 0269-9370
SP - 95
TI - Proviral HIV DNA sequencing to inform suitability for long-acting injectable cabotegravir/rilpivirine
T2 - AIDS
UR - http://dx.doi.org/10.1097/qad.0000000000004040
UR - https://doi.org/10.1097/qad.0000000000004040
UR - http://hdl.handle.net/10044/1/116459
VL - 39
ER -